VGT-309

DRUG3 trials

Sponsors

Vergent Bioscience, Inc., Stephan Rogalla

Conditions

Colorectal CancerLung CancerLung Metastases

Early Phase 1

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

TerminatedNCT06034197

Stephan RogallaColorectal Cancer

Start: 2024-02-07End: 2025-04-04Updated: 2026-04-08

Phase 2

Phase 2 Study of VGT-309 in Lung Cancer

CompletedNCT05400226

Vergent Bioscience, Inc.Lung Cancer

Start: 2022-05-24End: 2023-12-15Updated: 2024-10-17

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

CompletedNCT06145048

Vergent Bioscience, Inc.Lung Cancer, Lung Metastases

Start: 2023-10-05End: 2025-02-20Updated: 2026-05-13

Related Papers

Phase 2 multicenter clinical trial to evaluate the safety and efficacy of abenacianine for injection (VGT-309), a tumor-targeted, intraoperative molecular imaging agent, for patients undergoing surgery for cancer in the lung.

Journal of Clinical Oncology2025-05-28